argenx SE Key Executives
This section highlights argenx SE's key executives, including their titles and compensation details.
Find Contacts at argenx SE
(Showing 0 of )
argenx SE Earnings
This section highlights argenx SE's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-10-31 | $0.10 | $1.39 |
| Read Transcript | Q2 | 2024 | 2024-07-25 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.71 | $-1.04 |
Financial Statements
Access annual & quarterly financial statements for argenx SE, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.19B | $1.23B | $410.75M | $497.28M | $41.24M |
| Cost of Revenue | $227.29M | $117.83M | $29.43M | $- | $- |
| Gross Profit | $1.96B | $1.11B | $381.32M | $497.28M | $41.24M |
| Gross Profit Ratio | 89.62% | 90.39% | 92.83% | 100.00% | 100.00% |
| Research and Development Expenses | $949.30M | $859.49M | $663.37M | $580.52M | $370.88M |
| General and Administrative Expenses | $745.20M | $507.39M | $353.97M | $245.55M | $170.55M |
| Selling and Marketing Expenses | $306.99M | $202.15M | $115.95M | $59.97M | $- |
| Selling General and Administrative Expenses | $1.02B | $709.54M | $469.92M | $305.52M | $170.55M |
| Other Expenses | $16.58M | $-35.50M | $-31.63M | $-40.02M | $-22.58M |
| Operating Expenses | $1.98B | $1.53B | $1.10B | $846.02M | $518.86M |
| Cost and Expenses | $2.19B | $1.65B | $1.13B | $846.02M | $518.86M |
| Interest Income | $138.74M | $92.96M | $24.74M | $3.49M | $- |
| Interest Expense | $2.46M | $904.00K | $2.19M | $1.10M | $- |
| Depreciation and Amortization | $17.53M | $111.31M | $104.34M | $5.87M | $3.92M |
| EBITDA | $3.39M | $-192.28M | $-622.78M | $-392.78M | $-601.03M |
| EBITDA Ratio | 0.16% | -15.68% | -151.62% | -78.99% | -1457.30% |
| Operating Income | $-21.65M | $-425.05M | $-720.34M | $-348.75M | $-477.62M |
| Operating Income Ratio | -0.99% | -34.66% | -175.37% | -70.13% | -1158.06% |
| Total Other Income Expenses Net | $106.83M | $120.55M | $-8.97M | $-51.00M | $-127.73M |
| Income Before Tax | $85.18M | $-304.50M | $-729.31M | $-399.74M | $-605.35M |
| Income Before Tax Ratio | 3.89% | -24.83% | -177.56% | -80.39% | -1467.77% |
| Income Tax Expense | $-746.54M | $-9.44M | $-19.72M | $8.52M | $3.10M |
| Net Income | $833.04M | $-295.05M | $-709.59M | $-408.26M | $-608.46M |
| Net Income Ratio | 38.03% | -24.06% | -172.76% | -82.10% | -1475.29% |
| EPS | $13.92 | $-5.16 | $0.00 | $0.00 | $-13.40 |
| EPS Diluted | $12.78 | $-5.16 | $0.00 | $0.00 | $-13.40 |
| Weighted Average Shares Outstanding | 59.86M | 57.17M | - | - | 45.41M |
| Weighted Average Shares Outstanding Diluted | 65.18M | 57.17M | - | - | 45.41M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.30B | $841.96M | $686.31M | $468.20M | $302.91M | $111.35M | $26.04M | $420.44M | $22.64M | $30.53M | $31.29M | $51.30M | $8.73M | $20.50M | $17.37M | $23.88M | $10.18M | $6.97M | $5.61M | $4.35M |
| Cost of Revenue | $641.82M | $509.52M | $519.57M | $369.97M | $380.59M | $272.29M | $269.39M | $230.96M | $148.69M | $168.41M | $119.36M | $78.30M | $49.24M | $34.37M | $26.15M | $25.59M | $20.29M | $11.26M | $11.35M | $9.28M |
| Gross Profit | $661.43M | $332.44M | $166.74M | $98.23M | $-77.68M | $-160.93M | $-243.35M | $189.49M | $-126.04M | $-137.89M | $-88.08M | $-27.00M | $-40.51M | $-13.87M | $-8.78M | $-1.71M | $-10.12M | $-4.29M | $-5.74M | $-4.94M |
| Gross Profit Ratio | 50.75% | 39.48% | 24.29% | 20.98% | -25.65% | -144.52% | -934.56% | 45.07% | -556.71% | -451.72% | -281.53% | -52.64% | -463.82% | -67.68% | -50.52% | -7.15% | -99.37% | -61.52% | -102.44% | -113.52% |
| Research and Development Expenses | $514.67M | $414.01M | $451.20M | $331.15M | $359.06M | $266.20M | $269.39M | $230.96M | $148.69M | $168.41M | $119.36M | $78.30M | $49.24M | $34.37M | $26.15M | $25.59M | $20.29M | $11.26M | $11.35M | $9.28M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $14.13M | $- | $- | $- | $3.06M | $3.06M | $2.61M | $2.31M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.83M | $- | $- | $- | $885.00K | $- | $- | $- |
| Selling General and Administrative Expenses | $544.08M | $459.00M | $363.00M | $285.14M | $227.37M | $218.26M | $156.43M | $109.28M | $84.90M | $60.45M | $37.11M | $27.46M | $15.96M | $11.51M | $7.40M | $5.04M | $3.95M | $3.06M | $2.61M | $2.31M |
| Other Expenses | $-510.49M | $-410.92M | $-448.91M | $-329.43M | $-362.41M | $-266.20M | $-279.19M | $-230.96M | $-150.34M | $-169.25M | $-120.46M | $-78.30M | $-49.24M | $-34.37M | $-26.15M | $-25.59M | $-20.29M | $-11.26M | $-11.35M | $-9.28M |
| Operating Expenses | $562.71M | $462.09M | $365.30M | $286.86M | $224.03M | $218.26M | $146.63M | $109.28M | $83.25M | $59.62M | $36.01M | $27.46M | $15.96M | $11.51M | $7.40M | $5.04M | $3.95M | $3.06M | $2.61M | $2.31M |
| Cost and Expenses | $1.19B | $971.61M | $884.87M | $656.83M | $604.62M | $490.55M | $416.02M | $340.24M | $231.94M | $228.03M | $155.37M | $105.77M | $65.19M | $45.88M | $33.55M | $30.64M | $24.24M | $14.33M | $13.96M | $11.60M |
| Interest Income | $20.33M | $72.01M | $65.05M | $34.27M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $704.00K | $365.25K | $14.65M | $696.09K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $8.60M | $8.05M | $91.59M | $4.24M | $91.20M | $2.92M | $-817.98K | $2.50M | $-554.19K | $1.46M | $-335.00K | $915.00K | $259.00K | $215.00K | $215.00K | $210.00K | $178.00K | $145.00K | $106.00K | $85.00K |
| EBITDA | $125.94M | $-118.50M | $-104.68M | $-184.43M | $-213.86M | $-376.27M | $-400.60M | $82.71M | $-211.50M | $-196.87M | $-125.52M | $-53.55M | $-56.20M | $-25.17M | $-15.96M | $-6.54M | $-13.88M | $-7.21M | $-8.25M | $-7.17M |
| EBITDA Ratio | 9.66% | -14.07% | -15.25% | -39.39% | -70.60% | -337.90% | -1538.46% | 19.67% | -934.16% | -644.95% | -401.21% | -104.39% | -643.57% | -122.80% | -91.90% | -27.39% | -136.41% | -103.37% | -147.12% | -164.79% |
| Operating Income | $103.04M | $-129.65M | $-198.56M | $-188.63M | $-301.72M | $-379.19M | $-389.98M | $80.21M | $-209.30M | $-197.51M | $-124.09M | $-54.47M | $-56.46M | $-25.39M | $-16.18M | $-6.75M | $-14.06M | $-7.35M | $-8.36M | $-7.25M |
| Operating Income Ratio | 7.91% | -15.40% | -28.93% | -40.29% | -99.61% | -340.53% | -1497.69% | 19.08% | -924.42% | -647.02% | -396.63% | -106.18% | -646.54% | -123.85% | -93.13% | -28.27% | -138.16% | -105.45% | -149.01% | -166.74% |
| Total Other Income Expenses Net | $65.44M | $46.24M | $67.71M | $41.97M | $38.11M | $-47.52M | $-28.01M | $-16.12M | $-102.80M | $-1.92M | $10.64M | $9.70M | $10.72M | $5.28M | $-3.70M | $-845.00K | $45.00K | $-3.00K | $63.00K | $230.00K |
| Income Before Tax | $168.48M | $-83.41M | $-130.85M | $-146.66M | $-263.61M | $-426.71M | $-417.99M | $64.08M | $-312.09M | $-199.43M | $-113.44M | $-44.77M | $-45.74M | $-20.11M | $-19.88M | $-7.60M | $-14.02M | $-7.36M | $-8.29M | $-7.02M |
| Income Before Tax Ratio | 12.93% | -9.91% | -19.07% | -31.32% | -87.03% | -383.20% | -1605.24% | 15.24% | -1378.45% | -653.31% | -362.61% | -87.27% | -523.76% | -98.09% | -114.44% | -31.81% | -137.71% | -105.49% | -147.89% | -161.45% |
| Income Tax Expense | $-689.69M | $-52.57M | $24.78M | $-34.06M | $8.04M | $10.61M | $3.79M | $10.82M | $500.98K | $2.22M | $4.40M | $350.00K | $825.00K | $31.00K | $- | $597.00K | $- | $- | $- | $- |
| Net Income | $835.54M | $-30.37M | $-155.63M | $-112.94M | $-255.57M | $-416.10M | $-414.20M | $53.26M | $-312.59M | $-201.64M | $-117.84M | $-45.12M | $-46.56M | $-20.08M | $-19.88M | $-8.20M | $-14.02M | $-7.36M | $-8.29M | $-7.02M |
| Net Income Ratio | 64.11% | -3.61% | -22.68% | -24.12% | -84.37% | -373.67% | -1590.69% | 12.67% | -1380.67% | -660.57% | -376.68% | -87.96% | -533.21% | -97.94% | -114.44% | -34.31% | -137.71% | -105.49% | -147.89% | -161.45% |
| EPS | $11.78 | $-0.51 | $-2.65 | $-2.03 | $-4.62 | $-7.78 | $-8.04 | $0.99 | $-6.60 | $-4.64 | $-2.99 | $-1.19 | $-1.35 | $-0.62 | $-0.72 | $-0.38 | $-0.69 | $-0.42 | $-0.53 | $-0.45 |
| EPS Diluted | $11.78 | $-0.51 | $-2.65 | $-2.03 | $-4.62 | $-7.78 | $-8.04 | $0.99 | $-6.60 | $-4.64 | $-2.99 | $-1.19 | $-1.35 | $-0.62 | $-0.72 | $-0.38 | $-0.69 | $-0.42 | $-0.53 | $-0.45 |
| Weighted Average Shares Outstanding | 70.95M | 59.40M | 58.65M | 55.69M | 55.31M | 53.45M | 51.51M | 53.99M | 47.33M | 43.48M | 39.47M | 37.76M | 34.46M | 32.38M | 27.46M | 21.76M | 20.28M | 17.36M | 15.76M | 15.71M |
| Weighted Average Shares Outstanding Diluted | 70.96M | 59.40M | 58.65M | 55.69M | 55.31M | 53.45M | 51.51M | 53.99M | 47.34M | 43.48M | 39.47M | 37.76M | 34.46M | 32.38M | 27.46M | 21.76M | 20.28M | 17.36M | 15.76M | 15.71M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.45B | $2.05B | $800.74M | $1.33B | $1.22B |
| Short Term Investments | $1.81B | $1.13B | $1.39B | $1.00B | $779.65M |
| Cash and Short Term Investments | $3.26B | $3.18B | $2.19B | $2.34B | $2.00B |
| Net Receivables | $873.09M | $499.27M | $277.27M | $38.22M | $6.08M |
| Inventory | $393.10M | $310.55M | $228.35M | $109.08M | $25.20M |
| Other Current Assets | $185.89M | $134.07M | $76.02M | $58.95M | $29.27M |
| Total Current Assets | $4.71B | $4.12B | $2.77B | $2.54B | $2.06B |
| Property Plant Equipment Net | $43.52M | $22.68M | $16.23M | $15.84M | $11.58M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $181.44M | $125.23M | $174.90M | $171.68M | $167.34M |
| Goodwill and Intangible Assets | $181.44M | $125.23M | $174.90M | $171.68M | $167.34M |
| Long Term Investments | $49.70M | $47.16M | $40.48M | $53.17M | $6.31M |
| Tax Assets | $878.52M | $97.21M | $79.22M | $32.19M | $15.04M |
| Other Non-Current Assets | $998.98M | $126.45M | $49.23M | $34.42M | $22.14M |
| Total Non-Current Assets | $1.27B | $418.72M | $360.06M | $307.30M | $222.41M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $5.99B | $4.54B | $3.13B | $2.85B | $2.28B |
| Account Payables | $627.44M | $245.56M | $188.72M | $208.85M | $206.32M |
| Short Term Debt | $6.31M | $4.65M | $3.42M | $3.51M | $3.48M |
| Tax Payables | $13.39M | $4.33M | $3.18M | $4.32M | $3.50M |
| Deferred Revenue | $- | $- | $- | $- | $46.33M |
| Other Current Liabilities | $-464.63K | $168.46M | $106.96M | $84.56M | $68.87M |
| Total Current Liabilities | $646.67M | $422.99M | $302.28M | $301.24M | $328.49M |
| Long Term Debt | $31.39M | $15.35M | $9.01M | $7.96M | $6.18M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $269.04M |
| Deferred Tax Liabilities Non-Current | $- | $5.16M | $8.41M | $6.44M | $1.49M |
| Other Non-Current Liabilities | $1.74M | $1.45M | $870.00K | $417.00K | $156.00K |
| Total Non-Current Liabilities | $33.13M | $21.96M | $18.29M | $14.81M | $276.86M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $679.80M | $444.95M | $320.56M | $316.05M | $605.36M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.98M | $6.39M | $6.20M | $5.48M | $5.74M |
| Retained Earnings | $-1.52B | $-2.40B | $-2.11B | $-1.40B | $-991.93M |
| Accumulated Other Comprehensive Income Loss | $66.71M | $72.07M | $71.72M | $92.39M | $321.21M |
| Other Total Stockholders Equity | $6.75B | $6.42B | $4.85B | $3.84B | $2.34B |
| Total Stockholders Equity | $5.31B | $4.10B | $2.81B | $2.53B | $1.67B |
| Total Equity | $5.31B | $4.10B | $2.81B | $2.53B | $1.67B |
| Total Liabilities and Stockholders Equity | $5.99B | $4.54B | $3.13B | $2.85B | $2.28B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.99B | $4.54B | $3.13B | $2.85B | $2.28B |
| Total Investments | $1.82B | $1.18B | $1.43B | $1.06B | $785.96M |
| Total Debt | $37.70M | $20.00M | $12.43M | $11.46M | $9.66M |
| Net Debt | $-1.41B | $-2.03B | $-788.31M | $-1.32B | $-1.21B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.45B | $1.44B | $2.05B | $1.11B | $800.74M | $1.37B | $1.33B | $1.58B | $1.22B | $1.35B | $372.16M | $190.78M | $321.48M | $162.87M | $228.98M | $86.41M | $94.54M | $113.37M | $38.83M | $29.39M |
| Short Term Investments | $1.81B | $1.66B | $1.13B | $886.40M | $1.39B | $1.23B | $1.00B | $1.15B | $779.65M | $822.53M | $1.13B | $882.87M | $324.33M | $228.91M | $202.64M | $111.99M | $7.18M | $7.59M | $7.45M | $27.30M |
| Cash and Short Term Investments | $3.26B | $3.10B | $3.18B | $2.00B | $2.19B | $2.60B | $2.34B | $2.73B | $2.00B | $2.17B | $1.50B | $1.07B | $645.81M | $391.78M | $431.62M | $198.39M | $101.73M | $120.96M | $46.28M | $56.69M |
| Net Receivables | $873.09M | $655.56M | $499.27M | $354.61M | $277.27M | $113.93M | $38.22M | $12.05M | $7.44M | $10.05M | $31.88M | $6.34M | $3.65M | $12.14M | $3.60M | $5.07M | $2.24M | $2.06M | $1.48M | $2.30M |
| Inventory | $393.10M | $326.46M | $310.55M | $201.11M | $228.35M | $135.71M | $109.08M | $59.22M | $25.20M | $5.60M | $- | $2 | $2 | $2 | $2 | $1 | $2 | $2 | $1 | $1 |
| Other Current Assets | $185.89M | $179.42M | $134.07M | $138.82M | $76.02M | $82.31M | $58.95M | $62.40M | $27.91M | $12.22M | $10.14M | $11.39M | $5.36M | $7.41M | $4.83M | $4.64M | $3.08M | $3.17M | $496.36K | $491.26K |
| Total Current Assets | $4.71B | $4.26B | $4.12B | $2.69B | $2.77B | $2.93B | $2.54B | $2.86B | $2.06B | $2.20B | $1.54B | $1.09B | $654.82M | $411.33M | $440.06M | $208.09M | $107.06M | $126.18M | $48.26M | $59.49M |
| Property Plant Equipment Net | $43.52M | $36.93M | $22.68M | $14.68M | $16.23M | $14.24M | $15.84M | $11.39M | $11.58M | $9.90M | $9.18M | $6.69M | $942.58K | $869.46K | $811.00K | $1.01M | $805.60K | $813.12K | $272.23K | $319.66K |
| Goodwill | $- | $9.43M | $- | $15.84M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $181.44M | $132.35M | $125.23M | $174.02M | $174.90M | $171.29M | $171.68M | $- | $167.34M | $46.05M | $45.12M | $40.33M | $64.06K | $9.25K | $15.60K | $13.73K | $17.88K | $26.70K | $7.65K | $11.22K |
| Goodwill and Intangible Assets | $181.44M | $141.77M | $125.23M | $189.86M | $174.90M | $171.29M | $171.68M | $175.17M | $167.34M | $46.05M | $45.12M | $40.33M | $64.06K | $9.25K | $15.60K | $13.73K | $17.88K | $26.70K | $7.65K | $11.22K |
| Long Term Investments | $49.70M | $38.61M | $47.16M | $49.91M | $40.48M | $41.42M | $53.17M | $118.02M | $6.31M | $3.87M | $2.92M | $1.70M | $1.14K | $1.16K | $1.20K | $1.14K | $1.05K | $1.11K | $1.09K | $1.12K |
| Tax Assets | $878.52M | $174.63M | $97.21M | $138.77M | $79.22M | $54.27M | $32.19M | $16.25M | $15.04M | $2 | $- | $1 | $1 | $0 | $0 | $0 | $1 | $1 | $-0 | $0 |
| Other Non-Current Assets | $998.98M | $140.83M | $126.45M | $109.06M | $49.23M | $38.72M | $34.42M | $27.52M | $22.14M | $13.14M | $10.33M | $7.28M | $5.87M | $4.04M | $4.10M | $3.07M | $3.36M | $3.49M | $1.71M | $1.33M |
| Total Non-Current Assets | $1.27B | $532.77M | $418.72M | $502.28M | $360.06M | $319.95M | $307.30M | $348.36M | $222.41M | $72.96M | $67.54M | $56.01M | $6.88M | $4.92M | $4.92M | $4.09M | $4.18M | $4.33M | $2.00M | $1.67M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $1 | $1 | $- | $1 | $1 | $1 | $- |
| Total Assets | $5.99B | $4.80B | $4.54B | $3.19B | $3.13B | $3.25B | $2.85B | $3.21B | $2.28B | $2.27B | $1.61B | $1.15B | $661.70M | $416.26M | $444.98M | $212.19M | $111.24M | $130.51M | $50.25M | $61.15M |
| Account Payables | $627.44M | $280.63M | $245.56M | $195.27M | $188.72M | $167.24M | $208.85M | $239.44M | $206.32M | $143.79M | $65.64M | $62.61M | $27.63M | $24.93M | $5.27M | $14.95M | $4.61M | $5.73M | $4.97M | $5.43M |
| Short Term Debt | $6.31M | $5.85M | $4.65M | $3.20M | $3.42M | $3.49M | $3.51M | $3.45M | $3.48M | $2.54M | $2.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $13.39M | $13.95M | $4.33M | $4.61M | $3.18M | $3.42M | $4.32M | $1.15M | $3.50M | $484.73K | $386.00K | $1.66M | $941.43K | $653.25K | $716.22K | $682.93K | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $46.33M | $75.68M | $81.27M | $52.15M | $2.47M | $5.68M | $10.36M | $24.67M | $21.18M | $40.92M | $4.53M | $6.17M |
| Other Current Liabilities | $-464.63K | $199.20M | $168.46M | $114.72M | $106.96M | $90.46M | $84.56M | $- | $68.87M | $3 | $30.19M | $- | $14.78M | $1 | $13.06M | $1 | $8.21M | $1 | $1 | $- |
| Total Current Liabilities | $646.67M | $499.63M | $422.99M | $317.79M | $302.28M | $264.60M | $301.24M | $244.04M | $328.49M | $222.49M | $179.70M | $116.41M | $45.82M | $31.26M | $29.41M | $40.30M | $34.00M | $46.64M | $9.49M | $11.60M |
| Long Term Debt | $31.39M | $28.11M | $15.35M | $8.04M | $9.01M | $6.21M | $7.96M | $4.43M | $6.18M | $5.25M | $5.10M | $4.19M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $269.04M | $227.81M | $244.94M | $270.23M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $4.99M | $5.16M | $8.89M | $8.41M | $7.66M | $6.44M | $12.39M | $1.49M | $979.59K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.74M | $1.58M | $1.45M | $1.01M | $870.00K | $546.00K | $417.00K | $227.00K | $156.00K | $71.98K | $72.00K | $7.96K | $8.01K | $28.91K | $1.75M | $1.14K | $10.59M | $- | $- | $- |
| Total Non-Current Liabilities | $33.13M | $34.68M | $21.96M | $17.95M | $18.29M | $14.42M | $14.81M | $17.05M | $276.86M | $234.12M | $250.11M | $274.43M | $8.01K | $28.91K | $1.75M | $1.14K | $10.59M | $- | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $-0 | $- | $1 | $0 | $- | $- | $- | $- |
| Total Liabilities | $679.80M | $534.31M | $444.95M | $335.74M | $320.56M | $279.02M | $316.05M | $261.09M | $605.36M | $456.61M | $429.81M | $390.84M | $45.83M | $31.29M | $31.16M | $40.30M | $44.59M | $46.64M | $9.49M | $11.60M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $6.98M | $7.12M | $6.39M | $6.70M | $6.64M | $6.60M | $6.23M | $6.20M | $5.74M | $5.30M | $5.21M | $4.33M | $4.11M | $3.75M | $3.86M | $3.07M | $2.12M | $2.23M | $1.73M | $1.76M |
| Retained Earnings | $-1.52B | $-2.44B | $-2.40B | $-2.23B | $-2.11B | $-1.84B | $-1.40B | $-928.76M | $-991.93M | $-605.30M | $-383.48M | $-244.14M | $-194.01M | $-142.26M | $-120.65M | $-92.30M | $-76.24M | $-65.04M | $-55.89M | $-48.03M |
| Accumulated Other Comprehensive Income Loss | $66.71M | $945.06M | $72.07M | $710.09M | $71.72M | $527.31M | $92.39M | $431.75M | $321.21M | $119.55M | $53.04M | $54.74M | $35.40M | $23.80M | $14.11M | $10.73M | $7.88M | $6.43M | $5.08M | $3.92M |
| Other Total Stockholders Equity | $6.75B | $5.75B | $6.42B | $4.37B | $4.85B | $4.27B | $3.84B | $3.44B | $2.34B | $2.30B | $1.51B | $941.62M | $770.37M | $499.67M | $516.49M | $250.38M | $132.89M | $140.25M | $89.84M | $91.90M |
| Total Stockholders Equity | $5.31B | $4.26B | $4.10B | $2.86B | $2.81B | $2.97B | $2.53B | $2.95B | $1.67B | $1.82B | $1.18B | $756.55M | $615.87M | $384.97M | $413.81M | $171.88M | $66.65M | $83.87M | $40.76M | $49.56M |
| Total Equity | $5.31B | $4.26B | $4.10B | $2.86B | $2.81B | $2.97B | $2.53B | $2.95B | $1.67B | $1.82B | $1.18B | $756.55M | $615.87M | $384.97M | $413.81M | $171.88M | $66.65M | $83.87M | $40.76M | $49.56M |
| Total Liabilities and Stockholders Equity | $5.99B | $4.80B | $4.54B | $3.19B | $3.13B | $3.25B | $2.85B | $3.21B | $2.28B | $2.27B | $1.61B | $1.15B | $661.70M | $416.26M | $444.98M | $212.19M | $111.24M | $130.51M | $50.25M | $61.15M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.99B | $4.80B | $4.54B | $3.19B | $3.13B | $3.25B | $2.85B | $3.21B | $2.28B | $2.27B | $1.61B | $1.15B | $661.70M | $416.26M | $444.98M | $212.19M | $111.24M | $130.51M | $50.25M | $61.15M |
| Total Investments | $1.82B | $1.70B | $1.18B | $936.32M | $1.43B | $1.27B | $1.06B | $1.27B | $785.96M | $826.41M | $1.13B | $884.57M | $324.33M | $228.91M | $202.64M | $111.99M | $7.19M | $7.59M | $7.45M | $27.30M |
| Total Debt | $37.70M | $33.96M | $20.00M | $11.24M | $12.43M | $9.70M | $11.46M | $7.88M | $9.66M | $7.79M | $7.32M | $4.19M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-1.41B | $-1.40B | $-2.03B | $-1.10B | $-788.31M | $-1.36B | $-1.32B | $-1.57B | $-1.21B | $-1.34B | $-364.84M | $-186.59M | $-321.48M | $-162.87M | $-228.98M | $-86.41M | $-94.54M | $-113.37M | $-38.83M | $-29.39M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $804.13M | $-425.05M | $-720.34M | $-348.75M | $-477.62M |
| Depreciation and Amortization | $16.92M | $111.31M | $104.34M | $4.96M | $3.92M |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $227.02M | $232.97M | $157.03M | $179.37M | $96.93M |
| Change in Working Capital | $-551.68M | $-308.89M | $-375.72M | $-340.95M | $-13.71M |
| Accounts Receivables | $-408.43M | $-185.69M | $-222.26M | $-31.63M | $21.96M |
| Inventory | $-92.66M | $-83.03M | $-119.28M | $-83.88M | $-23.85M |
| Accounts Payables | $- | $- | $- | $- | $- |
| Other Working Capital | $-50.58M | $-40.17M | $-34.19M | $-225.44M | $-11.82M |
| Other Non Cash Items | $-579.14M | $-30.67M | $-28.11M | $-101.44M | $-7.99M |
| Net Cash Provided by Operating Activities | $-82.75M | $-420.33M | $-862.81M | $-606.81M | $-398.46M |
| Investments in Property Plant and Equipment | $-1.74M | $-40.52M | $-837.00K | $-3.62M | $-1.07M |
| Acquisitions Net | $-7.00M | $- | $-2.00M | $- | $- |
| Purchases of Investments | $- | $-1.27B | $-1.69B | $-228.24M | $- |
| Sales Maturities of Investments | $- | $1.54B | $1.26B | $- | $- |
| Other Investing Activities | $-708.86M | $76.47M | $-25.55M | $-115.21M | $345.76M |
| Net Cash Used for Investing Activities | $-717.59M | $308.21M | $-461.18M | $-347.07M | $344.69M |
| Debt Repayment | $-7.37M | $-3.80M | $-4.17M | $-3.85M | $-2.55M |
| Common Stock Issued | $- | $1.20B | $760.95M | $1.09B | $813.19M |
| Common Stock Repurchased | $-21.11M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $308.24M | $143.80M | $86.97M | $33.87M | $22.37M |
| Net Cash Used Provided by Financing Activities | $279.76M | $1.34B | $843.76M | $1.12B | $833.00M |
| Effect of Forex Changes on Cash | $-28.33M | $23.49M | $-53.70M | $-49.59M | $65.41M |
| Net Change in Cash | $-548.91M | $1.25B | $-533.94M | $117.87M | $844.64M |
| Cash at End of Period | $1.50B | $2.05B | $800.74M | $1.33B | $1.22B |
| Cash at Beginning of Period | $2.05B | $800.74M | $1.33B | $1.22B | $372.16M |
| Operating Cash Flow | $-82.75M | $-420.33M | $-862.81M | $-606.81M | $-398.46M |
| Capital Expenditure | $-1.74M | $-43.81M | $-103.82M | $-121.43M | $-5.14M |
| Free Cash Flow | $-81.61M | $-464.14M | $-966.63M | $-728.25M | $-403.60M |
Cash Flow Charts
| Breakdown | December 31, 2024 | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $835.54M | $-30.37M | $-155.63M | $-112.94M | $-255.57M | $-416.10M | $-414.20M | $53.26M | $-312.59M | $-201.64M | $-117.84M | $-45.12M | $-46.56M | $-20.08M | $-19.88M | $-8.20M | $-14.02M | $-7.36M | $-8.29M | $-7.02M |
| Depreciation and Amortization | $8.60M | $7.98M | $98.37M | $4.24M | $94.59M | $2.92M | $2.55M | $2.50M | $1.81M | $1.52M | $1.24M | $927.00K | $273.00K | $220.00K | $220.00K | $215.00K | $184.00K | $150.00K | $108.00K | $88.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $128.19M | $95.57M | $118.56M | $93.55M | $75.08M | $73.15M | $76.71M | $77.62M | $47.06M | $35.10M | $30.80M | $17.20M | $14.62M | $8.82M | $15.44M | $1.88M | $2.15M | $1.14M | $1.15M | $1.12M |
| Change in Working Capital | $-380.20M | $-165.83M | $-219.42M | $-148.68M | $-229.65M | $-124.23M | $-6.34M | $-129.23M | $-30.54M | $7.95M | $-25.42M | $-8.28M | $7.14M | $-9.71M | $1.59M | $-2.90M | $-426.00K | $-4.46M | $302.00K | $-1.31M |
| Accounts Receivables | $-314.21M | $-91.12M | $-106.56M | $-62.37M | $-141.12M | $-67.91M | $-24.19M | $-3.46M | $2.17M | $17.19M | $-22.79M | $-179.00K | $7.31M | $-7.36M | $2.17M | $-2.29M | $146.00K | $-760.00K | $317.00K | $-968.00K |
| Inventory | $-77.15M | $-15.00M | $-99.88M | $24.96M | $-86.52M | $-25.42M | $-43.81M | $-28.69M | $-15.04M | $-4.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $11.16M | $-59.71M | $-12.99M | $-111.28M | $-2.01M | $-30.89M | $61.65M | $-97.08M | $-17.68M | $-4.36M | $-2.63M | $-8.10M | $-168.00K | $-2.35M | $-580.00K | $-607.00K | $-572.00K | $-3.70M | $-15.00K | $-347.00K |
| Other Non Cash Items | $-551.67M | $-23.72M | $35.94M | $-97.74M | $-28.40M | $-7.75M | $5.88M | $-193.93M | $90.76M | $23.71M | $17.47M | $263.61M | $-1.73M | $-6.85M | $-18.60M | $-6.32M | $222.00K | $33.01M | $-1.72M | $1.68M |
| Net Cash Provided by Operating Activities | $40.45M | $-116.37M | $-122.18M | $-261.57M | $-343.95M | $-472.01M | $-335.40M | $-189.78M | $-203.51M | $-133.36M | $-93.75M | $228.34M | $-26.25M | $-27.59M | $-21.22M | $-15.32M | $-11.89M | $22.49M | $-8.45M | $-5.45M |
| Investments in Property Plant and Equipment | $-955.65K | $-20.64M | $-301.63K | $-443.28K | $-610.77K | $-174.67K | $-1.08M | $-2.01M | $-268.50K | $-658.53K | $-926.00K | $-678.00K | $-330.00K | $-292.00K | $-19.00K | $-326.00K | $-212.00K | $-628.00K | $-70.00K | $-204.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-195.81M | $-458.95M | $-197.89M | $483.40M | $-213.10M | $-221.60M | $128.70M | $-413.11M | $34.42M | $270.28M | $-220.16M | $-522.58M | $-79.10M | $-27.82M | $-70.65M | $-91.06M | $29.00K | $5.00K | $17.54M | $-454.00K |
| Net Cash Used for Investing Activities | $-196.76M | $-479.59M | $-198.20M | $482.96M | $-213.71M | $-221.77M | $127.62M | $-415.13M | $34.15M | $269.62M | $-221.08M | $-523.26M | $-79.43M | $-28.11M | $-70.67M | $-91.38M | $-183.00K | $-623.00K | $17.47M | $-658.00K |
| Debt Repayment | $- | $-3.36M | $- | $-2.00M | $- | $-2.12M | $- | $-1.52M | $- | $-1.03M | $- | $-536.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-19.38M | $-1.67M | $-10.45M | $-553.50K | $-5.47M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $250.75M | $42.45M | $1.16B | $59.63M | $38.60M | $773.62M | $15.83M | $931.85M | $13.45M | $727.71M | $480.03M | $179.87M | $243.00M | $1.68M | $212.17M | $93.19M | $39.00K | $44.58M | $238.00K | $- |
| Net Cash Used Provided by Financing Activities | $231.37M | $37.41M | $1.15B | $57.08M | $33.14M | $771.50M | $15.83M | $930.33M | $13.45M | $726.67M | $480.03M | $179.33M | $243.00M | $1.68M | $212.17M | $93.19M | $39.00K | $44.58M | $238.00K | $- |
| Effect of Forex Changes on Cash | $-15.51M | $-11.44M | $15.88M | $5.46M | $-4.57M | $-46.59M | $-25.25M | $-17.58M | $50.66M | $3.13M | $-1.70M | $2.34M | $2.86M | $4.02M | $-4.94M | $-854.00K | $11.00K | $-42.00K | $51.00K | $130.00K |
| Net Change in Cash | $-1.34B | $1.34B | $-1.02B | $1.02B | $-1.31B | $1.31B | $-1.33B | $1.33B | $-1.20B | $1.20B | $-167.79M | $167.79M | $-140.87M | $140.87M | $-75.53M | $75.53M | $-101.92M | $101.92M | $-26.21M | $26.21M |
| Cash at End of Period | $- | $1.34B | $- | $1.02B | $- | $1.31B | $- | $1.33B | $- | $1.20B | $- | $167.79M | $- | $140.87M | $- | $75.53M | $- | $101.92M | $- | $26.21M |
| Cash at Beginning of Period | $1.34B | $- | $1.02B | $- | $1.31B | $- | $1.33B | $- | $1.20B | $- | $167.79M | $- | $140.87M | $- | $75.53M | $- | $101.92M | $- | $26.21M | $- |
| Operating Cash Flow | $40.45M | $-116.37M | $-122.18M | $-261.57M | $-343.95M | $-472.01M | $-335.40M | $-189.78M | $-203.51M | $-133.36M | $-93.75M | $228.34M | $-26.25M | $-27.59M | $-21.22M | $-15.32M | $-11.89M | $22.49M | $-8.45M | $-5.45M |
| Capital Expenditure | $-955.65K | $-757.07K | $-307.44K | $-443.27K | $-610.77K | $-174.67K | $-1.08M | $-2.01M | $-268.50K | $-658.53K | $-926.00K | $-678.00K | $-330.00K | $-292.00K | $-19.00K | $-326.00K | $-212.00K | $-628.00K | $-70.00K | $-204.00K |
| Free Cash Flow | $39.50M | $-117.12M | $-122.49M | $-262.01M | $-344.56M | $-472.19M | $-336.48M | $-191.79M | $-203.78M | $-134.02M | $-94.68M | $227.66M | $-26.58M | $-27.88M | $-21.24M | $-15.65M | $-12.10M | $21.86M | $-8.52M | $-5.65M |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
$629.51
Stock Price
$38.44B
Market Cap
1.60K
Employees
Amsterdam, None
Location
Revenue (FY 2024)
$2.19B
78.6% YoY
Net Income (FY 2024)
$833.04M
382.3% YoY
EPS (FY 2024)
$12.78
347.6% YoY
Free Cash Flow (FY 2024)
$-81.61M
82.4% YoY
Profitability
Gross Margin
46.2%
Net Margin
37.0%
ROE
15.2%
ROA
13.4%
Valuation
P/E Ratio
50.36
P/S Ratio
18.63
EV/EBITDA
11513.44
Market Cap
$38.44B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-82.75M
80.3% YoY
Free Cash Flow
$-81.61M
82.4% YoY
Balance Sheet Summary
Total Assets
$5.99B
31.8% YoY
Total Debt
$37.70M
88.5% YoY
Shareholder Equity
$5.31B
23.7% YoY
Dividend Overview
No Dividend Data
argenx SE doesn't currently pay dividends.
argenx SE Dividends
Explore argenx SE's dividend history, including dividend yield, payout ratio, and historical payments.
argenx SE News
Read the latest news about argenx SE, including recent articles, headlines, and updates.
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. “Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs.
Wall Street Analysts Believe Argenx (ARGX) Could Rally 25.8%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Argenx (ARGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 27, 2025 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands. The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders.
US FDA approves syringe version of Argenx's immune disorder drug
The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option of at-home self administration, the company said on Thursday.
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for when and where to receive treatment – at home, while ‘on the go' or in a healthcare setting Approval reflects commitment to innovating the patient experience with individualized, safe and effective therapies April 10, 2025, 11:45 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART® Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). “Today's FDA approval provides a new self-injection option across both approved indications in the U.S. that is designed for patients who seek more independence with their treatment,” said Luc Truyen M.D.
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo's durable efficacy, sustained functional improvements and favorable safety profile argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK agonist) support pipeline-in-a-product development plan April 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of 15 abstracts, including an oral presentation, at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9, 2025 in San Diego, CA. The presentations showcase long-term data of VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile.
Stock Picks From Seeking Alpha's March 2025 New Analysts
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in San Diego, CA from April 5-9, 2025.
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel Derek Archila - Wells Fargo Yaron Werber - TD Cowen Victor Floch - BNP Paribas Rajan Sharma - Goldman Sachs Suzanne van Voorthuizen - Kempen Vikram Purohit - Morgan Stanley Matt Phipps - William Blair Gavin Clark-Gartner - Evercore ISI Samantha Semenkow - Citi Thomas Smith - Leerink Partners Leland Gershell - Oppenheimer Mehdi Goudarzi - Truist Securities Douglas Tsao - H. C. Wainwright Manos Mastorakis - Deutsche Bank Operator Good morning.
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and the U.S. The sales outlook for 2025 looks strong, and I expect Vyvgart to once again exceed Street expectations. The pipeline catalyst calendar is light for 2025, and several far more important readouts of Vyvgart and one of empasiprubart are expected in 2026.
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2024 and provided a fourth quarter business update. "In 2024, we significantly expanded our global patient reach with VYVGART, surpassing 10,000 patients across three indications,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
argenx to Present at TD Cowen 45th Annual Healthcare Conference
February 25, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
February 20, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 27, 2025 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2024 financial results and provide a fourth quarter business update.
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT.
argenx to Present at Upcoming Investor Conferences
November 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis), following analysis of topline data from the Phase 2 portion of the study. ALKIVIA will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ARGX.